Company intelligence / Profile preview

Respivant Sciences

San Diego, California, United Statesorpha.net ↗

Ownership: Private
Development stage: Phase 2

Overview

RVT‑1601 demonstrated statistically significant reduction in cough frequency among IPF patients after 14 days of treatment in a Phase 2a trial. A Phase 2b study was planned but current status suggests possible discontinuation. The company also completed a Phase 1 safety and PK study with RVT‑1601 in preterm infants at high risk for long-term respiratory morbidities. No recent late-stage clinical results reported as of early/mid‑2025.

Therapeutic areas: Pulmonology
Modalities: Small molecules (mast cell stabilizer)
Industry: Biotech

Drug pipeline

1 asset

RVT-1601

Partnerships

Parent relationship with Roivant; no major external pharma partnerships disclosed

Beyond the preview

Go deeper on Respivant Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Respivant Sciences.

Explore the full profile